Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
EMA Screener
SMA Screener
WMA Screener
OHLC Screener
Fibonacci Screener
VWAP Screener
Pivot Point Screener
Overlay Screener
Trend Indicator Screener
Volume Based Indicator Screener
Overbought/Sold Screener
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Dr Agarwals Health Care
Mid Cap•3,371 Employees•IPO 2025
Current Price
₹479.35
-1.75 (-0.36%)Updated
Today's Range
475.95
₹479.35
496.45
52 Week Range
52W Low₹327.00
52W High₹568.00
₹479.35
Downside46.59%
Upside18.49%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹14,338.71 Cr
Market Cap
Total market value of companyP/E Ratio
114.06
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
8.31
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹3.97
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
9.99%
ROCE
Return on Capital Employed. >15% is goodNet Margin
6.38%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
20.80%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
151.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.51
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹59.09
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
32.40%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Exceptional quarterly profit growth of 151.00% reflects robust operational performance.
- •Solid quarterly sales growth of 20.80% indicates increasing revenue and market penetration.
Weaknesses
5 points- •High P/E ratio of 157.00 suggests potential overvaluation and valuation corrections.
- •Low Return on Equity (ROE) of 4.76% indicates inefficient capital utilization.
Opportunities
5 points- •Robust healthcare industry growth driven by increasing demand and aging population.
- •Opportunity to expand into underserved regions or international markets leveraging expertise.
Threats
5 points- •Highly competitive hospital sector may lead to pricing pressures and margin erosion.
- •Evolving healthcare regulations and pricing controls could impact operational costs and revenue.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹532.88 | +₹53.53 | +11.17% |
| R3 | ₹512.38 | +₹33.03 | +6.89% |
| R2 | ₹504.42 | +₹25.07 | +5.23% |
| R1 | ₹491.88 | +₹12.53 | +2.61% |
| PIVOT | ₹483.92 | 4.57 | 0.95% |
| CURRENT | ₹479.35 | - | - |
| S1 | ₹430.38 | -₹48.97 | -10.22% |
| S2 | ₹450.88 | -₹28.47 | -5.94% |
| S3 | ₹463.42 | -₹15.93 | -3.32% |
| S4 | ₹471.38 | -₹7.97 | -1.66% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+131.8% vs avg
2.48L
(22 May 2026)Delivery %-9.4% vs avg
40.1%
(22 May 2026)Avg Volume (20D)20-day average
1.07L
(24 Apr - 22 May)Avg Delivery %Trend ↓
49.4%
(24 Apr - 22 May)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Apollo Hospitals Enterprise Ltd
1.09L ₹ Cr
Best Profit Growth
Fortis Healthcare Ltd
51.30 %
Highest Dividend Yield
Rainbow Childrens Medicare Ltd
0.51 %
Peer Comparison
| Company Name |
|---|
 Apollo Hospitals Enterprise Ltd |
 Aster DM Healthcare Ltd |
 Fortis Healthcare Ltd |
 Healthcare Global Enterprises Ltd |
 Jupiter Life Line Hospitals Ltd |
 |
 Krishna Institute of Medical Sciences Ltd |
 Global Health Ltd |
 Narayana Hrudayalaya Ltd |
 Rainbow Childrens Medicare Ltd |
 Yatharth Hospital & Trauma Care Services Ltd |
About
Dr Agarwals Health Care Ltd
Dr. Agarwal's Health Care Limited, operating under the name AGARWALEYE, is a prominent provider of comprehensive eye care services in India and abroad. Their business model centers around offering a wide spectrum of ophthalmic treatments and products, catering to diverse patient needs and preferences.
A significant portion of their revenue stems from surgical procedures. These include a comprehensive range of cataract surgeries, employing advanced techniques such as small incision cataract surgery, phacoemulsification, and even robotic cataract surgery. Beyond cataract care, they perform refractive surgeries to correct vision impairments and reduce or eliminate the need for corrective lenses. Further surgical offerings include retinal treatments, corneal transplants, oculoplasty (eyelid surgery), glaucoma surgeries, and pterygium removal.
Beyond surgical interventions, AGARWALEYE provides a robust suite of non-surgical services. These encompass diagnostic testing for various eye conditions, coupled with non-surgical treatments such as retinal laser therapy and dry eye treatments. The company also offers comprehensive consultation services, allowing patients to access expert ophthalmological advice and personalized care plans.
In addition to medical services, AGARWALEYE operates a retail arm, selling a range of products directly related to eye care. This includes eyeglasses, lenses, contact lenses, and frames, providing a convenient one-stop shop for patients requiring both treatment and optical products. They also sell eye care-related pharmaceutical products, further strengthening their integrated healthcare approach.
Established in 2010 and headquartered in Chennai, India, AGARWALEYE has steadily grown its presence both domestically and internationally, positioning itself as a key player in the global ophthalmology market. Their business strategy blends advanced surgical techniques, comprehensive non-surgical care, and a retail component to create a fully integrated eye care ecosystem.
COMPANY FACTS - AGARWALEYE
Registered Address
1St Floor,Buhari Towers,, No.4,Moores Road, Off Greams Road,, Near Asan Memorial School
Chennai
TAMIL NADU
IN
Tel: 914428116233
Website:https://www.dragarwal.com/
Investor Relations:http://dragarwals.co.in/dr-agarwals-health-care/#financials
Company Details
Group: Health Care Equipment & Services
Sector: Health Care
Industry: Health Care Providers & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 3,371
IPO Date: 04/02/2025
MANAGEMENT - AGARWALEYE
Dr. Amar Agarwal
Non-Executive Chairman of the Board
Dr. Adil Agarwal
Whole Time Director, Chief Executive Officer
Mr. Yashwanth Venkat
Chief Financial Officer
Dr. Anosh Agarwal
Whole Time Director, Chief Operating Officer
Mr. Thanikainathan Arumugam
Vice President - Corporate Affairs, Company Secretary, Compliance Officer
Mr. Ved Kalanoria
Non-Executive Nominee Director
Mr. Ankur Thadani
Non-Executive Nominee Director
Mr. Sanjay Anand
Non-Executive Independent Director
Mr. Venkatraman Balakrishnan
Non-Executive Independent Director
Ms. Archana Bhaskar
Non-Executive Independent Director
Mr. Nachiket Mor
Non-Executive Independent Director
Dr. Ranjan Pai
Non-Executive Independent Director
Investor Questions Answered
Dr Agarwals Health Care Ltd (AGARWALEYE) Stock FAQs
Get answers to the most common questions about Dr Agarwals Health Care Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Dr Agarwals Health Care Ltd (AGARWALEYE) is ₹479.35. Today, the stock has declined by ₹1.75 (0.36%), trading in a range of ₹475.95 to ₹496.45. The stock opened at ₹487.9 with a trading volume of 2,47,509 shares.
Dr Agarwals Health Care Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,338.71 crores, P/E ratio of 114.06, ROE of 0.00%, and ROCE of 9.99%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Dr Agarwals Health Care Ltd (AGARWALEYE) is ₹568, while the 52-week low is ₹327. Currently trading at ₹479.35, the stock is 63.2% away from its 52-week low and 15.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Dr Agarwals Health Care Ltd stock at ₹479.35 depends on multiple factors. The stock is currently trading with a P/E ratio of 114.06 and P/B ratio of N/A. Today's performance shows a loss of 0.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Dr Agarwals Health Care Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹479.35, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Dr Agarwals Health Care Ltd's key financial metrics include: P/E Ratio: 114.06, P/B Ratio: N/A, ROE: 0.00%, ROCE: 9.99%, Dividend Yield: 0.00%, EPS: ₹3.97, Book Value: ₹59.09, Debt-to-Equity: 0.51, and Current Ratio: N/A. The company's market cap stands at ₹14,338.71 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Dr Agarwals Health Care Ltd stock opened at ₹487.9 and is currently trading at ₹479.35, showing a decline of ₹1.75 (0.36%). The intraday high is ₹496.45 and low is ₹475.95. The trading volume stands at 2,47,509 shares, indicating moderate market participation today.
Dr Agarwals Health Care Ltd has a Price-to-Earnings (P/E) ratio of 114.06, which means investors are willing to pay ₹114.06 for every ₹1 of earnings. With an EPS of ₹3.97, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Dr Agarwals Health Care Ltd has a market capitalization of ₹14,338.71 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹479.35) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Dr Agarwals Health Care Ltd has a book value of ₹59.09 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹479.35, which is 711.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Dr Agarwals Health Care Ltd has a Return on Equity (ROE) of 0.00% and Return on Capital Employed (ROCE) of 9.99%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Dr Agarwals Health Care Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Dr Agarwals Health Care Ltd has a debt-to-equity ratio of 0.51, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Dr Agarwals Health Care Ltd has an Earnings Per Share (EPS) of ₹3.97, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹479.35 and P/E ratio of 114.06, investors are paying 114.06 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Dr Agarwals Health Care Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Dr Agarwals Health Care Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Dr Agarwals Health Care Ltd stock, consider: 1) Fundamental Analysis - Review P/E (114.06), ROE (0.00%), debt-to-equity (0.51), and growth rates. 2) Technical Analysis - Check 52-week range (₹327.00 - ₹568.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹479.35) with book value (₹59.09) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Dr Agarwals Health Care Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹479.35 is 47835x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Dr Agarwals Health Care Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹327.00 - ₹568.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.51 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,47,509 shares. 5) Valuation Risk - P/E of 114.06 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Dr Agarwals Health Care Ltd operates in the industry with key metrics: P/E ratio of 114.06, ROE of 0.00%, market cap of ₹14,338.71 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.51), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Dr Agarwals Health Care Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹479.35, with a 52-week range of ₹327.00 to ₹568.00. Based on fundamentals like P/E (114.06), ROE (0.00%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Dr Agarwals Health Care Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹479.35. 2) Fundamental Deterioration - Declining ROE (currently 0.00%), increasing debt (D/E: 0.51), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Dr Agarwals Health Care Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Related
Explore peers, sector trends and screeners related to this stock.
Menu